Table 1.
Baseline characteristics
| All (n = 200) | Plasma cell dyscrasias (n = 96) | B-cell malignancies (n = 84) | Other haematological malignancies (n = 20) | |
|---|---|---|---|---|
| Age (y), median (interquartile range) | 70 (59–76) | 70 (61.5–76) | 71 (59–76) | 56.5 (46.25–70.75) |
| BMI (kg/m2), median (interquartile range) | 24.00 (22.00–27.00) | 23.50 (22.00–27.00) | 24.00 (22.00–26.25) | 24.00 (20.50–26.00) |
| Female gender, n (%) | 83 (42) | 43 (45) | 33 (39) | 7 (35) |
| Disease response status, n (%) | ||||
| Partial/complete responses | 136 (68) | 70 (76) | 53 (63) | 13 (65) |
| Stable disease | 8 (4) | 6 (6) | 2 (2) | 0 (0) |
| Progressive disease | 36 (18) | 16 (17) | 16 (19) | 7 (35) |
| Treatment status, n (%) | ||||
| Naïve | 16 (8) | 4 (4) | 10 (12) | 0 (0) |
| On therapy | 151 (76) | 83 (87) | 53 (63) | 18 (90) |
| Off therapy— complete/partial response | 22 (11) | 8 (8) | 12 (14) | 1 (5) |
| Off therapy—relapse | 11 (6) | 1 (1) | 9 (11) | 1 (5) |
| Number of prior lines of therapy, n (interquartile range) | 5 (3–5) | 5 (3–6) | 3 (3–5) | 1 (1–2) |
| Previous autologous haematopoietic stem cell transplantation, n (%) | 39 (20) | 29 (30) | 6 (7) | 4 (20) |
| <12 mo before vaccination, n (%) | 5 (3) | 4 (4) | 0 | 1 (5) |
| ≥12 mo before vaccination, n (%) | 34 (17) | 25 (26) | 6 (7) | 3 (15) |
| Malignancy type, n (%) | — | Multiple myeloma 68 (71) Amyloidosis 28 (29) |
CLL 12 (14) FL 20 (24) MCL 9 (11) MZL 12 (14) DLBCL 31 (37) |
Hodgkin lymphoma 9 (45) T cell lymphoma 10 (50) Other 1 (5) |
| Receiving specific immunological therapy, n (%) | — | Anti-CD38 therapy: 66 (69) | Anti-CD20 therapy:70 (83) | Anti-CD20 therapy: 4 (20) |
| Previous vaccination in the last 6 mo | 52 (54) | 46 (55) | 1 (5) | |
| 6–12 mo before vaccination | 2 (2) | 7 (8) | 1 (5) | |
| >12 mo before vaccination | 12 (13) | 16 (19) | 2 (10) | |
| Third vaccine injection, n (%) | 78 (39) | 44 (46) | 27 (32) | 7 (35) |
BMI, body mass index; CLL, chronic lymphoid leukaemia; DLBC, diffuse large B cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.